Akynzeo

Chemical Namenetupitant or fosnetupitant and palonosetron
Dosage FormInjectable (intravenous; 235 mg fosnetupitant/0.25 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyHelsinn
Approval Year2018

Indication

  • Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Antiemetics: ASCO guideline update.2020Journal of Clinical Oncology